Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 2 days ago

Vera Therapeutics, Inc.: Avoro Capital Advisors LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Avoro Capital Advisors LLC amended its Schedule 13G filing on Vera Therapeutics, Inc., updating its beneficial ownership stake with the SEC under accession number 0000902664-26-004552. The filing was disclosed via SEC EDGAR. The amendment signals a change in Avoro's position in the clinical-stage biotech, though the exact size and direction of the stake were not specified in the headline disclosure. Investors watch 13G amendments for clues about institutional conviction in Vera's pipeline.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Avoro Capital Advisors LLC, Vera Therapeutics, Inc.